Immunogenicity of varicella zoster vaccine in pediatric liver transplantation.
liver transplantation
varicella zoster virus vaccine
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
22
06
2021
received:
15
03
2021
accepted:
16
07
2021
pubmed:
30
7
2021
medline:
13
4
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Pediatric liver transplant (LT) candidates often miss complete varicella-zoster virus (VZV) vaccination before LT. We aimed to evaluate the immunogenicity of two doses of VZV vaccines in pediatric LT candidates younger than 2 years and persistence of its immunogenicity after LT. Patients aged 9-24 months were enrolled before LT. The first dose of VZV vaccine was given at 9 months, and the second dose was given at between 1 to 3 months later, and at least 4 weeks before LT. Varicella-zoster IgG (VZG) was used to detect immunoglobulin G antibodies to VZV and was reported as a test value (TV). A test value ≥ 0.9 was considered as seropositive. TV was measured at enrollment, 1 month after the first and the second dose of VZV vaccine, before LT, and 3 and 6 months after LT. Fourteen children were enrolled in this prospective cohort study. The median age at the first and the second dose of VZV vaccine was 11.5 months (IQR 9-12) and 13 months (IQR 12-33), respectively. The seroconversion rate was 66.7% (8/12) and 70% (7/10) after the first and second VZV vaccine doses, respectively. Seven of nine patients who underwent LT had two doses of VZV vaccine. Six patients were seropositive before LT, which persisted at 3 to 6 months after LT. Of two patients who received only one dose, TV was not detected after LT. The two doses of VZV vaccine appeared to be more immunogenic than one dose in pediatric LT candidates aged less than 2 years.
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric liver transplant (LT) candidates often miss complete varicella-zoster virus (VZV) vaccination before LT. We aimed to evaluate the immunogenicity of two doses of VZV vaccines in pediatric LT candidates younger than 2 years and persistence of its immunogenicity after LT.
METHODS
METHODS
Patients aged 9-24 months were enrolled before LT. The first dose of VZV vaccine was given at 9 months, and the second dose was given at between 1 to 3 months later, and at least 4 weeks before LT. Varicella-zoster IgG (VZG) was used to detect immunoglobulin G antibodies to VZV and was reported as a test value (TV). A test value ≥ 0.9 was considered as seropositive. TV was measured at enrollment, 1 month after the first and the second dose of VZV vaccine, before LT, and 3 and 6 months after LT.
RESULTS
RESULTS
Fourteen children were enrolled in this prospective cohort study. The median age at the first and the second dose of VZV vaccine was 11.5 months (IQR 9-12) and 13 months (IQR 12-33), respectively. The seroconversion rate was 66.7% (8/12) and 70% (7/10) after the first and second VZV vaccine doses, respectively. Seven of nine patients who underwent LT had two doses of VZV vaccine. Six patients were seropositive before LT, which persisted at 3 to 6 months after LT. Of two patients who received only one dose, TV was not detected after LT.
CONCLUSIONS
CONCLUSIONS
The two doses of VZV vaccine appeared to be more immunogenic than one dose in pediatric LT candidates aged less than 2 years.
Substances chimiques
Antibodies, Viral
0
Herpes Zoster Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14934Informations de copyright
© 2021 Japan Pediatric Society.
Références
Prelog M, Zimmerhackl LB. Varicella vaccination in pediatric kidney and liver transplantation. Pediatr. Transplant. 2010; 14: 41-7.
Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: A household contact study. JAMA 2004; 292: 704-8.
Ceyhan M, Tezer H, Yildirim I. Secondary attack rate of hepatitis A, varicella and mumps in household settings and reliability of family history to detect seronegative children for necessity of vaccination. Scand. J. Infect. Dis. 2009; 41: 501-6.
Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int. J. Infect. Dis. 2004; 8: 259-70.
Heininger U, Seward JF. Varicella. Lancet. 2006; 368(9544): 1365-76.
Skull SA, Wang EE. Varicella vaccination-a critical review of the evidence. Arch. Dis. Child. 2001; 85: 83-90.
Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 2001; 344: 955-60.
Marin M, Guris D, Chaves SS et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007; 56(RR-11): 1-40.
Danzinger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 2009; 9(Suppl 4): S258-62.
Danziger-Isakov L, Kumar D, Practice AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am. J. Transplant. 2013; 13(Suppl 4): 311-7.
Wu JF, Ni YH, Chen HL, Hsu HY, Lai HS, Chang MH. Humoral immunogenicity to measles, rubella, and varicella-zoster vaccines in biliary atresia children. Vaccine 2009; 27: 2812-5.
Donati M, Zuckerman M, Dhawan A et al. Response to varicella immunization in pediatric liver transplant recipients. Transplantation 2000; 70(9): 1401-4.
McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74(2): 173-81.
Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawan Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac. J. Allergy Immunol. 2001; 19(2): 101-5.
Powell GM. Response to live attenuated measles vaccine in children with severe kwashiorkor. Ann. Trop. Paediatr. 1982; 2(3): 143-5.
Yang CH, Perumpail BJ, Yoo ER, Ahmed A, Kerner JA Jr. Nutritional needs and support for children with chronic liver disease. Nutrients. 2017; 9(10): 1127.
Kamath PS, Wiesner RH, Malinchoc M et al. A model to predic survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
Aziz A, Aziz S, Li DS et al. Efficacy of repeated high-dose hepatitis B vaccine (80 µg) in patients with chronic liver disease. J. Viral Hepat. 2006; 13: 217-21.
Funaki T, Shoji K, Miyata I et al. Serostatus following live attenuated vaccination administered before pediatric liver transplantation. Liver Transpl. 2015; 21: 774-83.